Cellular Immune Suppression in Paraneoplastic Neurologic Syndromes Targeting Intracellular Antigens | Neuro-oncology | JAMA Neurology | JAMA Network
[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Original Contribution
Sep 2012

Cellular Immune Suppression in Paraneoplastic Neurologic Syndromes Targeting Intracellular Antigens

Author Affiliations

Author Affiliations: The Rockefeller University (Drs Orange, Blachère, and Darnell, and Mss Parveen, Frank, and Tian), Hospital for Special Surgery (Dr Orange), Howard Hughes Medical Institute (Dr Darnell), Weill Cornell Medical College (Ms Buckley), Montefiore Einstein Medical Center (Dr Graber), New York, Westmed Medical Group, Bronxville (Dr Dousmanis), and Mount Kisco Medical Group, Brewster (Dr Marmur), New York.

Arch Neurol. 2012;69(9):1132-1140. doi:10.1001/archneurol.2012.595

Background Tumor treatment is the mainstay of therapy for paraneoplastic neurologic disorders (PNDs), but it is only effective in some cases and other treatment options are limited.

Objective To evaluate the short-term use of a combination of prednisone and tacrolimus for acute neurologic worsening in PND in which intracellular antigens are targeted.

Design Retrospective single-center case series of patients with PND treated with tacrolimus.

Setting The Rockefeller University Hospital, a research hospital in New York, New York.

Patients Twenty-six patients with PND with high titer (≥1:1000) anti-HuD, anti-Yo, or anti-CRMP5 autoantibodies were enrolled. Patients were referred from Memorial Sloan Kettering Cancer Center or self-referred. Two patients discontinued intervention owing to adverse events.

Interventions Patients were treated with tacrolimus, 0.15-0.30 mg/kg per day, in 2 divided oral doses with 60 mg per day of oral prednisone, tapered off during 1 to 4 weeks.

Main Outcome Measures The primary outcome measure was median survival. Neurologic examinations before and after treatment as well as adverse events are described.

Results Median survival time was 52 months from time of diagnosis. Some patients experienced neurologic improvement that was functionally meaningful. The incidence of adverse events was similar to that generally reported with tacrolimus.

Conclusions A short course of prednisone and tacrolimus to target central nervous system T cells in patients with PND with acute neurologic decline in which intracellular antigens are targeted was well tolerated and warrants further study.

Trial Registration clinicaltrials.gov Identifier: NCT00378326